AC IMMUNE SA (ACIU) Stock News

USA - NASDAQ:ACIU - CH0329023102 - Common Stock

2.9 USD

-0.06 (-2.03%)

Last: 10/17/2025, 8:00:00 PM

2.9 USD

0 (0%)

After Hours: 10/17/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ACIU Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Benzinga - Mentions: BFLY RLMD AQB LPTX ...

12 Health Care Stocks Moving In Friday's Intraday Session

17 days ago - By: Benzinga - Mentions: CCCC DBVT CLPT OVID ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

25 days ago - By: AC Immune SA

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

25 days ago - By: AC Immune SA

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

2 months ago - By: AC Immune SA

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

2 months ago - By: Zacks Investment Research - Mentions: ABEV ALX

New Strong Sell Stocks for August 6th

2 months ago - By: AC Immune SA

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

3 months ago - By: Zacks Investment Research - Mentions: FTRE

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: AC Immune SA

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: AC Immune SA

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: Zacks Investment Research - Mentions: ANAB

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

6 months ago - By: AC Immune SA

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

6 months ago - By: AC Immune SA

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

7 months ago - By: AC Immune SA

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

7 months ago - By: AC Immune SA

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

7 months ago - By: AC Immune SA

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

7 months ago - By: AC Immune SA

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

7 months ago - By: AC Immune SA

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

7 months ago - By: AC Immune SA

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

8 months ago - By: AC Immune SA

AC Immune to Participate in Upcoming Investor Conferences

10 months ago - By: AC Immune SA

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

10 months ago - By: AC Immune SA

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

a year ago - By: AC Immune SA

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

a year ago - By: AC Immune SA

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

a year ago - By: AC Immune SA

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

a year ago - By: AC Immune SA

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

a year ago - By: AC Immune SA

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

a year ago - By: AC Immune SA

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

a year ago - By: AC Immune SA

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

a year ago - By: AC Immune SA

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

a year ago - By: AC Immune SA

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

a year ago - By: AC Immune SA

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

a year ago - By: AC Immune SA

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

a year ago - By: AC Immune SA

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

a year ago - By: AC Immune SA

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024